Forward P/S Multiple: MindWalk Holdings (HYFT)

Public company logo of MindWalk Holdings (HYFT)

MindWalk Holdings (HYFT) relies on a narrow segment of molecule search and medical data, creating a dependency on pharmaceutical budgets. The forward price-to-sales valuation on the GURU.Markets daily price chart reflects the asset's dynamics, where the 3.80 level captures the current state. This is critical as the experimental nature of AI platforms carries risks, although the company's software effectively automates corporate IT infrastructure.

HYFT ipatherapeutics.com: Market Cap to Projected Revenue in the range 09/05/2025 - 11/17/2026

Summary analytical data breakdowns for MindWalk Holdings (HYFT)

- market price and analyst price targets:
- company stock exchange capitalization indicators:
Fundamental company analysis:HYFT (MindWalk)
Manufactured products of MindWalk Therapeutics

For MindWalk Holdings (HYFT), where the focus on AI expansion takes precedence over strict corporate control, monitoring the business's forward P/S ratio allows for an assessment of whether the market valuation is aligned with projected revenue. The trend of this multiple reveals the risk of valuation overheating or the pressure of operating expenses on margins, signaling a potential correction to the investor should momentum grow excessively.

Who MindWalk Holdings competes with

Forward P/S Multiple HLN (Haleon PLC)|Forward P/S Multiple Kenvue Corp KVUE|Verona Pharma PLC - Forward P/S Multiple|Market Cap to Future Revenue Ratio jyongbio.com|LGND: Forward P/S Multiple|Market Cap to Projected Revenue AMRX|Price-to-Projected Revenue Ratio Perrigo Company|Market Cap to Future Revenue Ratio Alvotech ALVO|Forward P/S Multiple LQDA|GLPG: Future Price to Revenue|Forward P/S Multiple ANIP (ANI Pharmaceuticals, Inc.)|Market Cap to Expected Sales Ratio MannKind Corp (MNKD)|AMPH: Forward Price-to-Revenue Multiple|Forward Price to Sales PCRX (Pacira)|ARS Pharmaceuticals (SPRY) - Price-to-Projected Revenue Ratio|Market Cap to Projected Revenue TBPH|AQST (Aquestive Corp) - Forward P/S Multiple|Forward Price-to-Revenue Multiple scPharmaceuticals Inc. (SCPH)|Forward Price-to-Revenue Multiple TECX (Tectonic Therapeutic, Inc.)|TNXP (Tonix Pharmaceuticals Holding) - Forward Price to Sales|Price-to-Projected Revenue Ratio SXT Pharmaceuticals SXTC|Forward Price to Sales EPRX|BHST - Price-to-Projected Revenue Ratio|eXoZymes (EXOZ) - Forward Price-to-Revenue Multiple|ORMP: Forward P/S Multiple|ENTX: Price to Expected Revenue Ratio|ABVC (ABVC BioPharma, Inc) - Forward P/S Multiple|Forward P/S Multiple cumberlandpharma.com|Price-to-Projected Revenue Ratio Quantum BioPharma (QNTM)|FibroGen (FGEN) - Projected Price to Revenue|Forward P/S Multiple TELO (telomirpharma.com)|RANI - Forward Price-to-Revenue Multiple|SNYR - Price-to-Projected Revenue Ratio|rallybio.com - Price to Expected Revenue Ratio|LEXX: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pulmatrix Inc|PTHL (Pheton Holdings) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Aptorum Group Limited APM|Price-to-Projected Revenue Ratio Lyra Therapeutics (LYRA)|Forward Price-to-Revenue Multiple Impact BioMedical Inc IBO|Price-to-Projected Revenue Ratio tnfpharma.com TNFA|Forward Price to Sales YCBD|PainReform Ltd - Forward P/S Multiple|Altamira Therapeutics Ltd (CYTO) - Forward Price-to-Revenue Multiple|lipella.com (LIPO) - Price-to-Projected Revenue Ratio|OptiNose (OPTN) - Forward P/S Multiple|PIRS (Pieris Pharmaceuticals Inc) - Forward P/S Multiple|PROC: Forward Price to Sales|Price-to-Projected Revenue Ratio Petros Pharmaceuticals, Inc. (PTPI)|Forward P/S Multiple Qilian International Corp (QLI)|ACELYRIN, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple tffpharma.com TFFP